These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36454477)

  • 1. Correction to: The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR
    Pasca S; Cojutti P; Pea F; Zanon E;
    J Thromb Thrombolysis; 2023 Jan; 55(1):195. PubMed ID: 36454477
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR
    Pasca S; PierGiorgio C; Pea F;
    J Thromb Thrombolysis; 2022 Nov; 54(4):593-596. PubMed ID: 36094687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.
    Zanon E; Pasca S; Sottilotta G; Molinari AC; Ferretti A; Di Gregorio P; Pollio B; Pizzuti M; Notarangelo LD; Biasoli C; Cojutti P; Pea F; Simioni P; Peyvandi F
    Blood Transfus; 2023 Jul; 21(4):350-355. PubMed ID: 36580025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.
    Sottilotta G; Luise F; Oriana V; Piromalli A; Santacroce R; Di Lelio A
    Hematol Rep; 2019 Feb; 11(1):7912. PubMed ID: 30915205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
    Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
    J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?
    Korte W
    J Blood Med; 2014; 5():107-13. PubMed ID: 25031548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
    Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
    Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
    Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
    Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy.
    Wang W; Wu S; Wang AY; Wu T; Luo H; Zhao JW; Chen J; Li Y; Ding H
    Front Med (Lausanne); 2022; 9():916620. PubMed ID: 36698821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
    Cojutti PG; Zanon E; Pasca S; Pea F;
    Clin Pharmacokinet; 2022 Apr; 61(4):505-513. PubMed ID: 34718987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
    Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
    Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
    Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
    J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
    Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
    Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
    Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
    Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
    Inbal A; Oldenburg J; Carcao M; Rosholm A; Tehranchi R; Nugent D
    Blood; 2012 May; 119(22):5111-7. PubMed ID: 22451421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
    Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
    J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.
    Karkouti K; von Heymann C; Jespersen CM; Korte W; Levy JH; Ranucci M; Sellke FW; Song HK
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):927-39. PubMed ID: 23820174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals.
    Beyerle A; Solomon C; Dickneite G; Herzog E
    Pharmacol Res Perspect; 2016 Apr; 4(2):e00227. PubMed ID: 27069637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys.
    Dodds MG; Visich JE; Vicini P
    AAPS J; 2005 Oct; 7(3):E693-703. PubMed ID: 16353946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
    Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
    Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.